Drugs / LMN-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06030414 | Oct → Dec 2023 | COVID-19 | Lumen Bioscience, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMN-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06030414 ↗ |
| Route | Intranasal | “Intranasally administered powder.” NCT06030414 ↗ |